A00533-1 Search Results


grα  (Boster Bio)
90
Boster Bio grα
Expression of glucocorticoid receptor and resistance gene at mRNA and protein level in each group. (A) Expression of <t>GRα</t> and β, transforming growth factor-β1 and activator protein-1 mRNA in each group. (B, C) Expression of GRα and β, transforming growth factor-β1 and activator protein-1 protein in each group. Glucocorticoid receptor (GR) α expression was significantly higher in Group VI in comparison with Group III ( ∗ P < 0.05); the expression <t>of</t> <t>GRβ</t> did not differ significantly. Meanwhile, p300 knockdown caused a significant increase in the expression of transforming growth factor-β1 and activator protein-1 at the levels of mRNA and protein, which suggests that p300 is involved in the occurrence of glucocorticoid resistance ( ∗ P < 0.05). Group II: Non-knockout model group; Group III: Non-knockout dexamethasone therapy group; Group VI: p300 knockout dexamethasone therapy group.
Grα, supplied by Boster Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/grα/product/Boster Bio
Average 90 stars, based on 1 article reviews
grα - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


Expression of glucocorticoid receptor and resistance gene at mRNA and protein level in each group. (A) Expression of GRα and β, transforming growth factor-β1 and activator protein-1 mRNA in each group. (B, C) Expression of GRα and β, transforming growth factor-β1 and activator protein-1 protein in each group. Glucocorticoid receptor (GR) α expression was significantly higher in Group VI in comparison with Group III ( ∗ P < 0.05); the expression of GRβ did not differ significantly. Meanwhile, p300 knockdown caused a significant increase in the expression of transforming growth factor-β1 and activator protein-1 at the levels of mRNA and protein, which suggests that p300 is involved in the occurrence of glucocorticoid resistance ( ∗ P < 0.05). Group II: Non-knockout model group; Group III: Non-knockout dexamethasone therapy group; Group VI: p300 knockout dexamethasone therapy group.

Journal: Chinese Medical Journal

Article Title: Role of p300 in the pathogenesis of Henoch-Schonlein purpura nephritis and as a new target of glucocorticoid therapy in mice

doi: 10.1097/CM9.0000000000000380

Figure Lengend Snippet: Expression of glucocorticoid receptor and resistance gene at mRNA and protein level in each group. (A) Expression of GRα and β, transforming growth factor-β1 and activator protein-1 mRNA in each group. (B, C) Expression of GRα and β, transforming growth factor-β1 and activator protein-1 protein in each group. Glucocorticoid receptor (GR) α expression was significantly higher in Group VI in comparison with Group III ( ∗ P < 0.05); the expression of GRβ did not differ significantly. Meanwhile, p300 knockdown caused a significant increase in the expression of transforming growth factor-β1 and activator protein-1 at the levels of mRNA and protein, which suggests that p300 is involved in the occurrence of glucocorticoid resistance ( ∗ P < 0.05). Group II: Non-knockout model group; Group III: Non-knockout dexamethasone therapy group; Group VI: p300 knockout dexamethasone therapy group.

Article Snippet: The primary antibodies used in this study were as follows: GRα (BOSTER Bio Inc, Wuhan, China), GRβ (Bioss Bio Inc, Beijing, China), TGF-β1 (BOSTER Bio Inc), activator protein (AP)-1 (Bioss Bio Inc), and GAPDH (Santa Cruz Bio Inc, Santa Cruz, USA).

Techniques: Expressing, Comparison, Knockdown, Knock-Out